ERS International Congress, Paris 2018

Browse by day:
Saturday, 15.09.2018
Sunday, 16.09.2018
Monday, 17.09.2018
Tuesday, 18.09.2018
Wednesday, 19.09.2018

 

View the presentations you missed during Congress!

More than 1,700 webcasts and slide presentations, 1,600 e-posters and 4,200 abstracts from the International Congress in Paris and are now available. 

Citations should be made in the following way: Authors. Title. Eur Respir J 2018; 52: Suppl. 62, abstract number.


Management of idiopathic interstitial pneumonias: established and new treatments

Thematic Poster
Chairs: N. Chaudhuri (Manchester (Greater Manchester), United Kingdom), C. Valenzuela (Alcobendas (Madrid), Spain), A. Morais (Maia, Portugal), S. Ohshimo (Hiroshima, Japan)
A self-reported qualitative assessment of yoga exercises delivered to patients with IPF and their caregivers.
N. Cassidy (Dublin 5, Ireland)
No content made available
No content made available
Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON
U. Costabel (Essen, Germany), M. Kreuter (Heidelberg, Germany), J. Song (Seul, Republic of Korea), J. Huggins (Charleston, South Carolina, United States of America), B. Wallaert (Lille, France), W. Stansen (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
Factors influencing Idiopathic Pulmonary Fibrosis (IPF) anti-fibrotic decisions in a single UK centre; patient and physician perspectives
A. Papadopoulos (Oxford, United Kingdom), S. Zannetos (Nicosia, Cyprus), R. Hoyles (Oxford, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
Investigation burden in patients with fibrotic interstitial lung disease in their terminal admission
H. Guo (Melbourne, Australia), J. Mann (Melbourne, Australia), N. Smallwood (Melbourne, Australia), N. Goh (Melbourne, Australia)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
Three-centre study (DZL) to investigate the effects of three-month whole-body vibration training on muscle strength, lung function, health-related quality of life and inflammation markers in patients with pulmonary fibrosis.
A. Koczulla (Marburg, Germany), T. Boeselt (Marburg, Germany), J. Koelpin (Marburg, Germany), C. Nell (Marburg, Germany), F. Kaufhold (Heidelberg, Germany), C. Vogelmeier (Marburg, Germany), F. Herth (Heidelberg, Germany), P. Alter (Marburg, Germany), M. Veith (Marburg, Germany), T. Greulich (Marburg, Germany), C. Kaehler (Wangen, Germany), M. Kreuter (Heidelberg, Germany)
Congress or journal article abstract
Congress or journal article abstract
Lessons learned when recruiting for an early Idiopathic Pulmonary Fibrosis (IPF) palliative care intervention
K. Lindell (Pittsburgh, United States of America), M. Nouraie (Pittsburgh, United States of America), S. Klein (Pittsburgh, United States of America), M. Klesen (Pittsburgh, United States of America), K. Gibson (Pittsburgh, United States of America), D. Kass (Pittsburgh, United States of America), M. Rosenzweig (Pittsburgh, United States of America)
Congress or journal article abstract
Congress or journal article abstract
Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
H. Morris (Manchester, United Kingdom), T. Marshall (Manchester, United Kingdom), K. Zakis (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Hayton (Manchester, United Kingdom), P. Rivera Ortega (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
Team support with pharmacists improved tolerability of antifibrotic agents for pulmonary fibrosis.
M. Kogo (Kobe, Japan), Y. Satsuma (Kobe, Japan), K. Kusuda (Kobe, Japan), H. Ikesue (Kobe, Japan), R. Mori (Kobe, Japan), D. Fujimoto (Kobe, Japan), K. Nagata (Kobe, Japan), A. Nakagawa (Kobe, Japan), R. Tachikawa (Kobe, Japan), K. Otsuka (Kobe, Japan), K. Tomii (Kobe, Japan)
Congress or journal article abstract
Congress or journal article abstract
Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
A. Belz (Chorzow, Poland), P. Debowska (Katowice, Poland), J. Warzecha (Zabrze, Poland), A. Gasiorek (Zabrze, Poland), D. Galczynska (Zabrze, Poland), S. Czyz (Zabrze, Poland), B. Ziaja (Zabrze, Poland), D. Jastrzebski (Zabrze, Poland), D. Ziora (Zabrze, Poland)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
M. Kato (Tokyo, Japan), T. Nakamura (Tokyo, Japan), K. Kono (Tokyo, Japan), M. Haraguchi (Tokyo, Japan), T. Yamada (Tokyo, Japan), H. Ihara (Tokyo, Japan), F. Takahashi (Tokyo, Japan), K. Takahashi (Tokyo, Japan)
Congress or journal article abstract
Congress or journal article abstract
Benefits of a pilot program of supervised exercise training in Idiopathic Pulmonary Fibrosis
J. Bordas Martinez (Barcelona, Spain), J. Palma Lopez (Barcelona, Spain), M. Sampere Aymerich (Barcelona, Spain), A. Bachs Salvado (Barcelona, Spain), L. Planas Cerezales (Barcelona, Spain), I. Callorda Boniatti (Barcelona, Spain), F. Lopez Beltran (Barcelona, Spain), R. Planas Balague (Barcelona, Spain), J. Dorca Sargatal (Barcelona, Spain), M. Molina Molina (Barcelona, Spain), V. Vicens Zygmunt (Barcelona, Spain)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
Long-term (4 years) experience of Nintedanib in IPF patients in Crete: A real life data study
K. Antoniou (Herakleion, Greece), A. Trachalaki (Herakleion, Greece), E. Vasarmidi (Herakleion, Greece), G. Margaritopoulos (London, United Kingdom), G. Papastratigakis (Herakleion, Greece), E. Bibaki (Herakleion, Greece), E. Stamataki (Herakleion, Greece), G. Meletis (Herakleion, Greece), N. Tzanakis (Herakleion, Greece)
Congress or journal article abstract
Congress or journal article abstract
Palliative and symptomatic care of patients with fibrotic interstitial lung disease
J. Mann (Melbourne, Australia), H. Guo (Melbourne, Australia), N. Goh (Melbourne, Australia), N. Smallwood (Melbourne, Australia)
Congress or journal article abstract
Congress or journal article abstract
Multidisciplinary management of interstitial lung diseases in a tertiary centre: A prospective study.
C. Biglia (Bruxelles, Belgium), B. Ghaye (Bruxelles, Belgium), G. Reychler (Bruxelles, Belgium), V. Lacroix (Bruxelles, Belgium), F. Tamirou (Bruxelles, Belgium), D. Hoton (Bruxelles, Belgium), T. Pieters (Bruxelles, Belgium), A. Froidure (Bruxelles, Belgium)
Congress or journal article abstract
Congress or journal article abstract
Idiopathic Pulmonary Fibrosis (IPF): Should it be all about the FVC?
S. Boot (Leeds, United Kingdom), L. Horgan (Leeds, United Kingdom), L. Flint (Leeds, United Kingdom), T. Sutherland (Leeds, United Kingdom), P. Beirne (Leeds, United Kingdom)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
M. Naqvi (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. West (London, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
Real-life efficacy of Pirfenidone in a cohort of patients with IPF in Northern Greece
S. Kotoulas (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), I. Organtzis (Thessaloniki, Greece), G. Pitsiou (Thessaloniki, Greece), A. Papaioannou (Thessaloniki, Greece), C. Euthymiou (Thessaloniki, Greece), I. Stanopoulos (Thessaloniki, Greece), V. Mourouzidou (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece)
Congress or journal article abstract
Congress or journal article abstract
Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis
L. Schwarzkopf (Neuherberg, Germany), S. Witt (Neuherberg, Germany), J. Waelscher (Heidelberg, Germany), M. Polke (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
Experience of patients treated with nintedanib in the Community of Madrid. REFIPIMAD Registry
M. Nieto Barbero (Madrid, Spain), L. Gómez Carrera (Madrid, Spain), M. Rodríguez Nieto (Madrid, Spain), Á. Casanova Espinosa (Madrid, Spain), R. Laporta Hernández (Madrid, Spain), B. López-Muñiz Ballesteros (Madrid, Spain), C. Valenzuela (Madrid, Spain), T. Bilbao-Goyoaga Arenas (Madrid, Spain), G. Mora Ortega (Madrid, Spain), M. Río Ramírez (Madrid, Spain)
Congress or journal article abstract
Congress or journal article abstract
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial
S. Homma (Tokyo, Japan), Y. Kondoh (Aichi, Japan), M. Kato (Tokyo, Japan), T. Hoshino (Fukuoka, Japan), H. Mukae (Nagasaki, Japan), M. Bando (Tochigi, Japan), T. Suda (Hamamatsu, Japan), T. Kido (Fukuoka, Japan), Y. Tanino (Fukushima, Japan), T. Kishaba (Okinawa, Japan), N. Hattori (Hiroshima, Japan), Y. Taguchi (Nara, Japan), T. Saitoh (Ibaraki, Japan), Y. Nishioka (Tokushima, Japan), K. Kuwano (Tokyo, Japan), K. Kishi (Tokyo, Japan), N. Inase (Tokyo, Japan), S. Sasaki (Chiba, Japan), H. Takizawa (Tokyo, Japan), T. Johkoh (Osaka, Japan), F. Sakai (Saitama, Japan), S. Sakamoto (Tokyo, Japan)
Congress or journal article abstract
Congress or journal article abstract